Abstracts Archive - Page 379 of 2425 - ACR Meeting Abstracts

Abstract Number: 1418 • ACR Convergence 2022
Change in Disease Activity and Occurrence of Adverse Events After Initiation of Etanercept in Pediatric Patients with Juvenile Psoriatic Arthritis in the CARRA Registry
Colleen Correll¹, Scott Stryker², David Collier³, Anne Dennos⁴, Stephen Balevic⁵, Thomas Phillips⁵ and Tim Beukelman⁶, ¹University of Minnesota, Minneapolis, MN, ²Amgen Inc., San Francisco, CA, ³Amgen Inc., Simi Valley, CA, ⁴Duke University, Durham, NC, ⁵Duke Clinical Research Institute, Durham, NC, ⁶Childhood Arthritis and Rheumatology Research Alliance (CARRA), Birmingham, AL
Background/Purpose: Juvenile psoriatic arthritis (JPsA) constitutes ~5% of juvenile idiopathic arthritis (JIA). Several therapeutics are available for JPsA; however, given the low JPsA incidence, important…
Abstract Number: 1403 • ACR Convergence 2022
Herpes Zoster in Rheumatoid Arthritis: Prospective Single University Center Study
Lucia Cristina Dominguez Casas¹, Mª Paz Rodriguez Cundin², Trinidad Dierssen Sotos³, Nuria Vegas Revenga⁴, Alfonso Corrales⁵, Miguel Ángel González-Gay⁶ and Ricardo Blanco⁷, ¹Hospital Universtario San Agustin, Oviedo, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Universidad de Cantabria, Santander, Spain, ⁴Hospital Galdakao- Usansolo, Galdakao, Spain, ⁵Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Patients with Rheumatoid arthritis (RA) have an increased risk of infections due to the disease itself, and/or immunosuppressive therapy. The risk of herpes zoster…
Abstract Number: 1417 • ACR Convergence 2022
Clinical and Demographic Characteristics of Patients with RF+/ACPA+ RA and First-Line TNF Inhibitor versus Abatacept Treatment Choice in Real-World Clinical Practice
Gordon Lam¹, Hanke Zheng², Emily Bland³, Vardhaman Patel⁴, Laetitia N’Dri⁵, Parisa Asgarisabet³, Keith Wittstock⁴, Cherrishe Brown-Bickerstaff³, Mark Chaballa², Bruce Feinberg³, Vadim Khaychuk⁶ and Andrew J Klink³, ¹Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²Bristol Myers Squibb, Princeton, NJ, ³Cardinal Health, Dublin, OH, ⁴Bristol Myers Squibb, Lawrence Township, NJ, ⁵Bristol Myers Squibb, Princeton, ⁶Bristol Myers Squibb, Pennington, MA
Background/Purpose: Early intensive treatment (tx) is an accepted paradigm in the tx of patients (pts) with RA with poor prognostic factors (eg, RF/ACPA seropositivity); however,…
Abstract Number: 1416 • ACR Convergence 2022
Bioactive Lipid Profiling Can Identify Dynamic Biomarkers in Response to Biologic Therapy Result of the CorEvitas CERTAIN Comparative Effectiveness Study
Roxana Coras¹, Mona Alotaibi², Dimitrios Pappas³, Joel Kremer⁴, Jeffrey Curtis⁵, Arthur Kavanaugh⁶, Ted Mikuls⁷, Geoffrey Thiele⁸, mohit jain² and Monica Guma⁹, ¹University of California San Diego, San Diego, CA, ²Department of Medicine, School of Medicine, University of California San Diego, San Diego, CA, ³CorEvitas, LLC, Waltham, MA, ⁴The Corrona Research Foundation, Delray Beach, FL, ⁵University of Alabama at Birmingham, Hoover, AL, ⁶University of California San Diego, La Jolla, CA, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁸University of Nebraska Medical Center, Omaha, NE, ⁹UCSD, La Jolla, CA
Background/Purpose: Bioactive lipids comprise distinct classes of bioactive molecules with functions that are critical for joint disease, including regulation of not only inflammation but also…
Abstract Number: 1412 • ACR Convergence 2022
Coronary Microvascular Dysfunction in Patients with Rheumatoid Arthritis and Diabetes Mellitus: A Cross-sectional Study with 13NH3 Myocardial PET/CT
Bas Dijkshoorn¹, Remco Knol², Friso Van Der Zant², Michael Nurmohamed³ and Suat Simsek², ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Noord-west Ziekenhuis groep, Alkmaar, Netherlands, ³Amsterdam University Medical Center, Kortenhoef, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease. This risk is similar to that of diabetes mellitus (DM). There have…
Abstract Number: 1363 • ACR Convergence 2022
Impact of SARS-CoV-2 on the Clinical Presentation of Juvenile Idiopathic Inflammatory Myopathies
Jessica Perfetto¹, Donna Yoo², Carolina Tamashiro³, Megan Perron⁴, Natalia Vasquez Canizares⁵ and Dawn Wahezi⁶, ¹The Children's Hospital at Montefiore, Division of Rheumatology, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³The Children's Hospital at Montefiore, Department of Pediatrics, Bronx, NY, ⁴Children's Hospital Colorado, Division of Rheumatology, Aurora, CO, ⁵Children's Hospital at Montefiore/ Albert Einstein College of Medicine, New York, NY, ⁶Children's Hospital at Montefiore, Bronx, NY
Background/Purpose: Viruses can trigger juvenile idiopathic inflammatory myopathies (JIIM), including juvenile dermatomyositis (JDM), juvenile polymyositis (JPM), and overlap myositis. There is growing evidence that infection…
Abstract Number: 1395 • ACR Convergence 2022
Comparative Safety of Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Patients Undergoing Treatment for Rheumatoid Arthritis
Yao-Fan Fang¹ and Lai-Chu See², ¹Chang Gung Memorial Hospital, Taoyuan, Taiwan, ²Biostatistics Core Laboratory, Molecular Medicine Research centre, Chang Gung University, Taoyuan, Taiwan
Background/Purpose: Since 2010, biological disease-modifying antirheumatic drugs (bDMARDs) have been the dominant mode of treatment for rheumatoid arthritis (RA). However, the safety of DMARDs, such…
Abstract Number: 1408 • ACR Convergence 2022
In RA Patients Without Prevalent CVD, Incident CVD Is Only Associated with Traditional Risk Factors: A 20-year Follow up in the CARRÉ Cohort Study
Reinder Raadsen¹, Rabia Agca², Maarten Boers³, Vokko van Halm², Mike Peters⁴, Yvo Smulders², Joline Beulens², Marieke Blom², Coen Stehouwer⁵, Alexandre Voskuyl², Willem Lems⁶ and Michael Nurmohamed⁷, ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Amsterdam UMC, Amsterdam, Netherlands, ³Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁴Amsterdam UMC; UMC Utrecht, Amsterdam, Netherlands, ⁵MUmc, Amsterdam, Netherlands, ⁶Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁷Amsterdam University Medical Center, Kortenhoef, Netherlands
Background/Purpose: We have documented that patients with rheumatoid arthritis (RA) are at increased risk to develop cardiovascular disease (CVD) compared to the general population, even…
Abstract Number: 1310 • ACR Convergence 2022
Is the Trabecular Bone Score (TBS) a Useful Tool in Patients with Diffuse Idiopathic Skeletal Hyperostosis (DISH)?
Bjoern Buehring¹, David Kiefer², Celina Mueller², Roshnak Parvaee², Marianti Ifanti², Ioana Andreica³, Timm Westhoff⁴, Rainer Wirth⁴, Xenofon Baraliakos⁵, Nina Babel⁴ and Juergen Braun², ¹Bergisches Rheuma-Zentrum, Wuppertal, Germany, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ⁴Marienhospital Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Patients with rheumatic and musculoskeletal diseases (RMD) have an increased fracture risk (FxR). Diffuse idiopathic skeletal hyperostosis (DISH) is a non-inflammatory disease characterized by…
Abstract Number: 1372 • ACR Convergence 2022
Telemedicine Use in the Assessment of Juvenile Dermatomyositis and Polymyositis: A Survey of Caregivers and Patients
Stacey Tarvin¹, Y. Ingrid Goh², Nicole Taylor³, Bianca Lang⁴, Marietta De Guzman⁵, Julie Fuller⁶, Kristin Houghton⁷, Susan Kim⁸, Vanessa Carbone⁹, Kathryn Cook¹⁰, Tanya Slater⁹, Angela Robinson¹¹, Liza McCann¹², Charalampia Papadopoulou¹³, Clarissa Pilkington¹⁴, Phoebe Rushe¹⁵ and Peter Blier¹⁶, ¹Riley Hospital for Children at Indiana University Health, Indianapolis, IN, ²Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute, Toronto, ON, Canada, ³University of Indianapolis, Indianapolis, IN, ⁴Dalhousie University - Halifax, Halifax, NS, Canada, ⁵Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, ⁶UT Southwestern, Frisco, TX, ⁷University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁸UCSF Benioff Children's Hospital, San Francisco, CA, ⁹The Hospital for Sick Children, Toronto, ON, Canada, ¹⁰Akron Children's Hospital, Copley, OH, ¹¹Cleveland Clinic, Cleveland, OH, ¹²Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ¹³UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Section Head Infection, Immunology, and Rheumatology, London, United Kingdom, ¹⁴Great Ormond Street Hospital, London, United Kingdom, ¹⁵Royal Liverpool University Hospital, Liverpool, United Kingdom, ¹⁶Retired, Amherst, MA
Background/Purpose: Care of patients with juvenile myositis (JM) involves complex assessments performed by highly trained specialists. Restrictions surrounding the COVID-19 pandemic resulted in many patients…
Abstract Number: 1419 • ACR Convergence 2022
Time to Discontinuation and Effectiveness with Baricitinib in Rheumatoid Arthritis: 12-Month European Data from a Multinational, Prospective, Observational Study
Rieke Alten¹, Gerd Burmester², Marco Matucci-Cerinic³, Andrew Ostor⁴, Liliana Zaremba-Pechmann⁵, Tamas Treuer⁶, Khai Jing Ng⁶, Jens Gerwien⁶, Kathryn Gibson⁷ and Bruno Fautrel⁸, ¹SCHLOSSPARK KLINIK, University Medicine Berlin, Berlin, Germany, ²Charité University Medicine Berlin, Berlin, Germany, ³University of Florence, Florence, Italy, ⁴Cabrini Hospital, Monash University & Emeritus Research, Melbourne, Australia, ⁵HaaPACS GmbH, Schriesheim, Germany, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly and Company, Indianapolis, United States of America, Sydney, Australia, ⁸Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France
Background/Purpose: RA-BE-REAL is a 3-year, multinational, prospective, observational study of adult patients with rheumatoid arthritis (RA) evaluating time to discontinuation of initial RA treatment. Baricitinib…
Abstract Number: 1404 • ACR Convergence 2022
Machine Learning Model to Accurately Identify Rheumatoid Arthritis Patients Using Raw Electronic Health Record Data
Vinit Gilvaz¹, Anthony Reginato², Deepan Dalal³ and Brad Crough⁴, ¹Brown University, East Providence, RI, ²Brown University, Providence, RI, ³Brown University School of Medicine, Providence, RI, ⁴Brown Physicians Inc., Providence, RI
Background/Purpose: Patients with chronic medical conditions like rheumatoid arthritis (RA) have a wealth of clinical data stored within their electronic medical records (EMR). Artificial intelligence…
Abstract Number: 1299 • ACR Convergence 2022
Hitting the Target Together: Supporting Shared Decision-Making with Juvenile Idiopathic Arthritis (JIA) Patients Followed in the Out-Patient Rheumatology Setting at the Hospital for Sick Children
Jo-Anne Marcuz¹, Brian Feldman², Y. Ingrid Goh³, Niina Kim⁴, Piya Lahiry⁵, Deborah Levy², Elizaveta Limenis⁶, Jeanine McColl⁷, Christine O'Brien⁸, Susan Paetkau⁴, Shirley Tse², Kristi Whitney⁸ and Ronald Laxer², ¹Division of Rheumatology and Department of Rehabilitation, The Hospital for Sick Children; University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵Division of Rheumatology, The Hospital for Sick Children; Department of Pediatrics, University of Toronto, Toronto, ON, Canada, ⁶Division of Rheumatology, The Hospital for Sick Children; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, The Hospital for Sick Children; University of Toronto, Toronto, ON, Canada, ⁸Division of Rheumatology and Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common chronic rheumatic disease in children with significant morbidity that extends into adulthood. Despite advances in effective…
Abstract Number: 1415 • ACR Convergence 2022
Different Bioactive Lipid Profile Predicts Response to TNF or IL6 Inhibitors in Rheumatoid Arthritis: Result of the CorEvitas CERTAIN Comparative Effectiveness Study
Mona Alotaibi¹, Roxana Coras², Dimitrios Pappas³, Ted Mikuls⁴, Joel Kremer⁵, Geoffrey Thiele⁶, mohit jain¹ and Monica Guma⁷, ¹Department of Medicine, School of Medicine, University of California San Diego, San Diego, CA, ²University of California San Diego, San Diego, CA, ³CorEvitas, LLC, Waltham, MA, ⁴Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵The Corrona Research Foundation, Delray Beach, FL, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷UCSD, La Jolla, CA
Background/Purpose: Circulating bioactive lipids can provide information about the pathogenesis of specific diseases and potentially help predict therapeutic response. Choosing the right biological therapy earlier…
Abstract Number: 1383 • ACR Convergence 2022
Differences in Clinical and Patient-reported Outcomes in Juvenile Dermatomyositis by Race and Ethnicity
Rebecca Olveda, Jessica Neely and Susan Kim, UCSF Benioff Children's Hospital, San Francisco, CA
Background/Purpose: Previous studies in juvenile dermatomyositis (JDM) have shown that patients from minoritized ethnicities and those with lower family income are more likely to have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].